| Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 17224888 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The importance of the dissolution and prevention of thrombosis in treating patients with ST-segment elevation myocardial infarction (STEMI) has motivated the development of novel therapies targeting platelet aggregation and thrombus formation. In contemporary practice, the current challenge is the integration of these therapies into reperfusion strategies that may include fibrinolytic therapy or percutaneous coronary revascularization (PCI). Evidence from clinical trials shows that addition of glycoprotein IIb/IIIa inhibition to PCI for treatment of STEMI has substantially lowered the incidence of recurrent ischemic events and improved early survival. In contrast, current trials evaluating a strategy termed facilitated PCI, or planned early PCI after pharmacologic reperfusion therapy, have presently demonstrated an increased risk of bleeding events and mortality. Additional trials have extended the role of antithrombotic agents to STEMI that previously were reserved for patients undergoing elective revascularization or among those treated with non-ST-segment elevation acute coronary syndromes. For example, the recent studies have demonstrated the benefit of clopidogrel treatment among STEMI patients treated with fibrinolysis in reducing the incidence of infarct artery reocclusion and improving early survival. Other anticoagulants under investigation in the management of STEMI include enoxaparin, bivalirudin, and fondaparinux. This review summarizes the current status of pharmacologic and invasive strategies for the treatment of STEMI and describes recent and ongoing directions for clinical investigation. |
| | |
Authors:
|
David E Kandzari |
Related Documents
:
|
23281408 - Signaling effectors underlying pathologic growth and remodeling of the heart. 23177488 - Detection and prevention of cardiac complications of cancer chemotherapy. 17916168 - Improvement in door-to-balloon times in management of acute st-segment elevation myocar... 19918168 - Outcomes of nonemergent percutaneous coronary intervention with and without on-site sur... 22072938 - Cardioprotective effects of glycyrrhizic acid against isoproterenol-induced myocardial ... 14962488 - Reduced reactive o2 species formation and preserved mitochondrial nadh and [ca2+] level... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Reviews in cardiovascular medicine Volume: 7 Suppl 4 ISSN: 1530-6550 ISO Abbreviation: Rev Cardiovasc Med Publication Date: 2006 |
Date Detail:
|
Created Date: 2007-01-16 Completed Date: 2008-04-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100960007 Medline TA: Rev Cardiovasc Med Country: United States |
Other Details:
|
Languages: eng Pagination: S29-37 Citation Subset: IM |
Affiliation:
|
Interventional Cardiology and Genomic Sciences, Duke Clinical Research Institute, Durham, North Carolina, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary
/
adverse effects* Anticoagulants / adverse effects, therapeutic use* Blood Platelets / drug effects* Cardiovascular Diseases / blood, etiology, mortality, prevention & control* Clinical Trials as Topic Combined Modality Therapy Drug Therapy, Combination Fibrinolysis / drug effects Fibrinolytic Agents / adverse effects, therapeutic use* Hemorrhage / chemically induced Humans Myocardial Infarction / drug therapy, mortality, therapy* Platelet Aggregation / drug effects Platelet Aggregation Inhibitors / adverse effects, therapeutic use* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Pyridines / therapeutic use Research Design Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Pyridines; 0/thienopyridine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergenc...
Next Document: Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet ...